<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00381953</url>
  </required_header>
  <id_info>
    <org_study_id>HCV02-01</org_study_id>
    <nct_id>NCT00381953</nct_id>
  </id_info>
  <brief_title>High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV</brief_title>
  <official_title>A Comparative Study of High-dose Interferon Alfa-2a and Pegylated Interferon Alfa-2a for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Liver Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foundation for Liver Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of virological breakthrough/relapse rate after dose adjustments and sustained&#xD;
      virological response rate will be assessed by the type of induction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare pharmacokinetics by IFN assays and pharmacodynamics&#xD;
      by patient's HCVRNA suppression of 360 mug peginterferon QW, 9 MU interferon daily or 4,5 MU&#xD;
      interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of&#xD;
      treatment. Comparison of virological breakthrough/relapse rate after dose adjustments and&#xD;
      sustained virological response rate will be assessed by the type of induction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCV RNA suppression of 360 mug peginterferon alfa-2a QW, 9 MU interferon alfa-2a daily or 4,5 interferon alfa-2a daily in combination with 180 mug peginterferon alfa-2a QW</measure>
    <time_frame>week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the virological breakthrough/relapse rate after dose adjustments (at 4,24,72) weeks.</measure>
    <time_frame>week 4, 24 and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the sustained virological response rate at 24 weeks after end of treatment.</measure>
    <time_frame>week 24 follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>360 PEG IFN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>360 mug peginterferon alfa-2a QW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9 MU + 180 PEG IFN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4,5 MU IFN + 180 PEG IFN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <arm_group_label>360 PEG IFN</arm_group_label>
    <arm_group_label>4,5 MU IFN + 180 PEG IFN</arm_group_label>
    <arm_group_label>9 MU + 180 PEG IFN</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alfa-2a</intervention_name>
    <arm_group_label>4,5 MU IFN + 180 PEG IFN</arm_group_label>
    <arm_group_label>9 MU + 180 PEG IFN</arm_group_label>
    <other_name>Intron-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>360 PEG IFN</arm_group_label>
    <arm_group_label>4,5 MU IFN + 180 PEG IFN</arm_group_label>
    <arm_group_label>9 MU + 180 PEG IFN</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  chronic hepatitis C&#xD;
&#xD;
          -  detectable serum HCV-RNA&#xD;
&#xD;
          -  elevated serum ALT activity documented on at least two occasions within the past 12&#xD;
             months, with at least one during the 90 day screening period preceding the initiation&#xD;
             of test drug dosing&#xD;
&#xD;
          -  liver biopsy findings (during screening or within previous 12 months) consistent with&#xD;
             active fibrosis (haemophiliacs are excluded from biopsies)&#xD;
&#xD;
          -  compensated liver disease (Child-Pugh Grade A clinical classification)&#xD;
&#xD;
          -  negative urine or blood pregnancy test (for women of childbearing potential)&#xD;
             documented within the 24-hour period prior to the first dose of study drug&#xD;
&#xD;
          -  all fertile males and females receiving ribavirin and their fertile or potentially&#xD;
             fertile partners must be advised to use two forms of effective contraception&#xD;
             (combined) during treatment and during the 6 months after end of treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history or other evidence of severe illness, malignancy or any other condition which&#xD;
             would make the patient, in the opinion of the investigator, unsuitable for the study&#xD;
&#xD;
          -  women with ongoing pregnancy or breast feeding&#xD;
&#xD;
          -  therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment&#xD;
             (including supraphysiologic doses of steroids and radiation) &lt;3 months prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  any investigational drug &lt;6 weeks prior to the first dose of study drug positive test&#xD;
             at screening for HBsAg, anti-HIV Ab history or other evidence of bleeding from&#xD;
             esophageal varices, ascites, or other conditions consistent with decompensated liver&#xD;
             disease (Child-Pugh Grade B or C clinical classification)&#xD;
&#xD;
          -  Signs or symptoms of hepatocellular carcinoma&#xD;
&#xD;
          -  history or other strong evidence of a medical condition associated with chronic liver&#xD;
             disease other than HCV (e.g., primary hemochromatosis, autoimmune hepatitis, metabolic&#xD;
             liver disease, alcoholic liver disease, toxin exposures&#xD;
&#xD;
          -  Hb &lt;7.5 mmol/l in women or &lt;8.6 mmol/l in men at screening&#xD;
&#xD;
          -  any patient with an increased baseline risk for anaemia (e.g. thalassemia,&#xD;
             spherocytosis, etc) or for whom anaemia would be medically problematic neutrophil&#xD;
             count &lt;1500 cells/mm3 or platelet count &lt;80,000 cells/mm3 at screening&#xD;
&#xD;
          -  serum creatinine level &gt;1.5 times the upper limit of normal at screening&#xD;
&#xD;
          -  history of severe psychiatric disease, especially depression&#xD;
&#xD;
          -  history of a severe seizure disorder or current anticonvulsant use&#xD;
&#xD;
          -  history of immunologically mediated disease&#xD;
&#xD;
          -  history or other evidence of chronic pulmonary disease associated with functional&#xD;
             limitation&#xD;
&#xD;
          -  history of severe allergies&#xD;
&#xD;
          -  history of symptomatic and/or significant cardiovascular disease&#xD;
&#xD;
          -  poorly controlled diabetes mellitus&#xD;
&#xD;
          -  history of major organ transplantation with an existing functional graft&#xD;
&#xD;
          -  hyper- or hypothyroidism&#xD;
&#xD;
          -  evidence of severe retinopathy&#xD;
&#xD;
          -  evidence of drug abuse (including excessive alcohol consumption within one year before&#xD;
             study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob J. de Knegt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 27, 2006</study_first_submitted>
  <study_first_submitted_qc>September 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2006</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

